… We recruited patients with idiopathic DCM who were either (1) … ‐specific exons or other
infrequently used TTN exons were … Adverse clinical outcomes such as heart failure hospitalization…

… -altered PC including clinical outcomes on MAPK pathway … and encouraging outcomes in
patients within BRAF Exon 15 … significant for either RAF subgroups (A) Exon 15, (B) Exon 11…

… -TKIs can be applied in NSCLC patients with either EGFR exon 19 del or exon 21
Leu858Arg point mutations, although they showed better responses in exon 19 del patients [103]. …

… , consisting of RET rearrangements identified by either FISH or NGS testing. For patients …
or equal to 15% of tumor cells positive with either split signals or isolated 3′ probes for RET…

… the baseline characteristics and clinical outcomes among patients … as either positive or
negative by abstractors using either … Two patients with RET fusions had an exon 19 mutation (one …

… Cox proportional hazards models were used to analyze the clinical outcomes of patients …
osimertinib has shown significant clinical efficacy in NSCLC patients with either EGFR-sensitive …

… GIST patients either carrying a genomic alteration on exon 18 D842V (… exon 12 V561D,
exon 14 K646E) and three patients showing insertions/deletions (indel) either in exon 12 or exon …

… diagnosed NSCLC and EGFR mutation (exon 19 deletion or exon 21 L858R substitution),
and … In the FLAURA trial comparing patients treated with either osimertinib (n = 279) or a first-…

… diagnosed with different stages of NSCLC, having either a c-MET exon 14 skipping mutation
or an … Crizotinib was found to be an optimal treatment for NSCLC harboring c-MET exon 14 …

… Of the 238 DMD patients in our cohort with deletion mutations not involving either exon 1 or
79… For clinical outcomes, we looked at wheelchair use (combined permanent and intermittent …